Therefore, we investigated whether ADAM12 may serve as a novel biomarker and/or therapeutic target in CRC, using human CRC cell lines, human CRC tissues, and an in vivo xenograft tumor model. This evidence concerns the gene ADAM12 and colorectal carcinoma.